Kura Oncology, Inc. (KURA) Stock Analysis

Kura Oncology won FDA approval for KOMZIFTI (ziftomenib) in November 2025, its first and only approved product, indicated for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia who have exhausted other options -- a patient population Kura estimates represents a $350 million to $400 million initial U.S. annual market opportunity, growing to roughly $7.0 billion if ziftomenib expands into frontline AML combinations. Kura co-commercializes KOMZIFTI in the U.S. with Kyowa Kirin under an equal profit-and-loss split, while Kyowa Kirin holds commercialization rights outside the United States.

KOMZIFTI, a once-daily oral menin inhibitor, is approved based on the Phase 1/2 KOMET-001 trial, which showed a 21.4% complete-remission-or-better rate in 112 relapsed/refractory NPM1-mutated AML patients; Kura is now running two Phase 3 registrational trials (KOMET-017) testing ziftomenib alongside both intensive and non-intensive chemotherapy in newly diagnosed AML, aiming to expand beyond its current monotherapy label. At least 80% of private payors had established coverage policies within 90 days of approval, though some require patients to try KOMZIFTI before other menin inhibitors. Kura's only approved-product competitor is revumenib (REVUFORJ), another FDA-approved menin inhibitor. Beyond menin inhibition, Kura's farnesyl transferase inhibitor darlifarnib is being evaluated in combination with targeted therapies for renal cell carcinoma, non-small cell lung cancer, colorectal cancer and pancreatic cancer, broadening the pipeline beyond AML.